SynthesisPeerJ2023
The prevalence of clarithromycin-resistant
Synthesis in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Clarithromycin-resistant Helicobacter pylori in Africa: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- Insights intoFrontiers in microbiology · 2024Pooled it
- Adjunctive Synbiotic Therapy forLife (Basel, Switzerland) · 2026Review
- Review
- Efficacy and Safety of Tegoprazan inPharmaceuticals (Basel, Switzerland) · 2026Review
- Integrative profiling ofMicrobial genomics · 2026Article
- Comparative molecular profiling of Helicobacter pylori infection and antibiotic genotypic resistance in paired gastric mucosa, gastric juice, and stool samples.Scientific reports · 2025Article
- Design and Characterization of Novel Gastroretentive Drug Delivery System of Antibiotics and Piperine for the Eradication ofMolecular pharmaceutics · 2025Article
- Addressing the global challenge ofGut microbes reports · 2025Article
- MicroRNA-Mediated Regulatory Networks inBiochemistry research international · 2025Review
- Recommendations and Adjuvant Therapies to Mitigate Clarithromycin-ResistantInfection and drug resistance · 2025Review
- Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries.United European gastroenterology journal · 2024Observational
- ImprovedEuropean journal of medicinal chemistry reports · 2024Article
- An Update on Eradication ofMiddle East journal of digestive diseases · 2024Review
- Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.Scientific reports · 2024Article
- Crises in Antimicrobial Stewardship: Misuse of Clarithromycin forPharmacoepidemiology · 2024Article
- Polymorphism of virulence genes and biofilm associated with in vitro induced resistance to clarithromycin in Helicobacter pylori.Gut pathogens · 2023Article
- Epidemiology ofAntibiotics (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Knowledge of global clarithromycin (CLA)-resistant rates of Method: A comprehensive search was performed for relevant literature until April 2021 in PubMed, Embase, and Web of Science databases. Freeman-Tukey double arcsine transformation was performed to estimate the weighted pooled prevalence of resistance. Results: The meta-analysis included 248 articles. The prevalence of CLA-resistant Conclusion: Overall CLA resistance rate was 27.53%, worldwide. The difference in CLA resistance rate among the included studies can be due to several reasons such as differences in antibiotic prescription rates in various geographic areas, use of different breakpoints or inaccurate criteria in performed studies, and the emergence of multidrug-resistant (MDR) strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.